A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

William A. Sheremata, T. L. Vollmer, L. A. Stone, A. J. Willmer-Hulme, M. Koller

Research output: Contribution to journalArticle

111 Scopus citations

Abstract

A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

Original languageEnglish (US)
Pages (from-to)1072-1074
Number of pages3
JournalNeurology
Volume52
Issue number5
DOIs
StatePublished - Mar 23 1999

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A safety and pharmacokinetic study of intravenous natalizumab in patients with MS'. Together they form a unique fingerprint.

  • Cite this

    Sheremata, W. A., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J., & Koller, M. (1999). A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology, 52(5), 1072-1074. https://doi.org/10.1212/wnl.52.5.1072